Share

EORTC hosting session at ICTR-PHE 2016 in Geneva

The EORTC will host a session at ICTR-PHE 2016, the International Conference on Translational Research in Radio-Oncology – Physics for Health in Europe, from 11:00 – 12:30 on Thursday, 18 February 2016 in Session Room 2 at the Centre International de Conférences Genève in Geneva, Switzerland.

This session will be chaired by Prof Wilfried Budach of Universitaetsklinik in Dusseldorf, Germany. The session will highlight several areas of current EORTC research where the EORTC is making significant contributions towards advancing therapies for patients with cancer.

Speakers include Dr. Damien Weber of the Paul Scherrer Institute Center for Proton Therapy in Villigen, Switzerland, who will present the EORTC radiotherapy quality assurance platform.

Following him, Dr. Sofia Rivera of the Institut Gustave Roussy in Villejuif, France, will discuss Synergy of targeted agents and radiotherapy.

Dr. Rivera will be followed by Dr. Monika Hegi of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, who will talk about Lessons from translational research in EORTC Glioma trials.

Dr. Conny Vrieling of the Clinique des Grangettes in Chêne-Bougeries, Switzerland, will close the EORTC session with a talk concerning Data from the EORTC Cancer Survivorship Task Force.

Back to news list

Related News

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

  • New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024

  • Late Breaking Results from the EORTC 1333/PEACE III phase III trial

  • EORTC’s presence at ESMO 2024